Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.
Takeshi HatanakaSatoru KakizakiAtsushi HiraokaToshifumi TadaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraNoritomo ShimadaKazuhito KawataHisashi KosakaTakaaki TanakaHideko OhamaKazuhiro NousoAsahiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiAtsushi NaganumaYohei KoizumiShinichiro NakamuraKouji JokoMasaki KaiboriHiroko IijimaYoichi HiasaTakashi Kumadanull nullPublished in: Hepatology international (2022)
The CRAFITY score is simple and could be useful for predicting therapeutic outcomes and treatment-related adverse events.